Figure 2.

Mean Weight Change (kg) From Baseline Over Time in 5 Short-Term, Double-Blind, Placebo-Controlled Fixed-Dose Studies of Desvenlafaxine in Patients With MDD^a

^aData from 5 short-term, fixed-dose studies.^{13,14,16,21,22}

^bFinal refers to the final evaluation and includes data from all patients using the last assessment prior to discontinuation.

*P < .001 within-group change from baseline.

^†P < .001 desvenlafaxine versus placebo.

^‡P < .01 versus desvenlafaxine 50 mg.

^§P ≤ .001 versus desvenlafaxine 50 mg.

^‖P < .05 within-group change from baseline.

**P < .001 versus desvenlafaxine 100 mg.

^††P < .05 versus desvenlafaxine 200 mg.

^‡‡P < .05 desvenlafaxine versus placebo.

^§§P < .01 desvenlafaxine versus placebo.

Abbreviations: BL = baseline, MDD = major depressive disorder.